BR112022011147A2 - Compostos para inibir fatores de neovascularização e uso dos mesmos - Google Patents

Compostos para inibir fatores de neovascularização e uso dos mesmos

Info

Publication number
BR112022011147A2
BR112022011147A2 BR112022011147A BR112022011147A BR112022011147A2 BR 112022011147 A2 BR112022011147 A2 BR 112022011147A2 BR 112022011147 A BR112022011147 A BR 112022011147A BR 112022011147 A BR112022011147 A BR 112022011147A BR 112022011147 A2 BR112022011147 A2 BR 112022011147A2
Authority
BR
Brazil
Prior art keywords
compounds
inhibit neovascularization
factors
neovascularization factors
present specification
Prior art date
Application number
BR112022011147A
Other languages
English (en)
Portuguese (pt)
Inventor
Heon Kang Byoung
kim So-yeon
Gu Yoon Nam
Lee Changwook
Ho Park Dong
Original Assignee
Ulsan Nat Inst Science & Tech Unist
Smartin Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulsan Nat Inst Science & Tech Unist, Smartin Bio Inc filed Critical Ulsan Nat Inst Science & Tech Unist
Publication of BR112022011147A2 publication Critical patent/BR112022011147A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022011147A 2019-12-16 2020-12-16 Compostos para inibir fatores de neovascularização e uso dos mesmos BR112022011147A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190168238 2019-12-16
PCT/KR2020/018475 WO2021125800A1 (ko) 2019-12-16 2020-12-16 신생혈관형성인자의 억제를 위한 화합물 및 그 용도

Publications (1)

Publication Number Publication Date
BR112022011147A2 true BR112022011147A2 (pt) 2022-08-23

Family

ID=76477859

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011147A BR112022011147A2 (pt) 2019-12-16 2020-12-16 Compostos para inibir fatores de neovascularização e uso dos mesmos

Country Status (9)

Country Link
US (1) US12545695B2 (cg-RX-API-DMAC7.html)
EP (1) EP4079309A4 (cg-RX-API-DMAC7.html)
JP (1) JP7831775B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210076875A (cg-RX-API-DMAC7.html)
CN (1) CN114901290B (cg-RX-API-DMAC7.html)
AU (1) AU2020409912A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011147A2 (cg-RX-API-DMAC7.html)
CA (1) CA3164800A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021125800A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3164800A1 (en) 2019-12-16 2021-06-24 Unist(Ulsan National Institute Of Science And Technology) Compound for inhibiting neovascularization factors and use thereof
JP7766885B2 (ja) * 2021-06-15 2025-11-11 スマーティン バイオ インコーポレイテッド Trap1阻害剤およびその用途
KR20220167945A (ko) * 2021-06-15 2022-12-22 주식회사 스마틴바이오 Trap-1 억제제
IT202200008621A1 (it) * 2022-04-29 2023-10-29 Sifi Spa Composizione farmaceutica in microemulsione per il trattamento dei disturbi del segmento anteriore dell'occhio
KR102894216B1 (ko) * 2022-12-15 2025-12-18 울산과학기술원 Trap-1 억제제
KR20260076808A (ko) 2024-11-20 2026-05-28 주식회사 스마틴바이오 Trap1 억제제를 포함하는 암 예방 또는 치료용 병용투여 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
DE69818675T2 (de) 1997-07-29 2004-07-29 Alcon Laboratories, Inc., Fort Worth Galaktomannanpolymere und borat enthaltende augenarzneimittel
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20060229278A1 (en) 1998-11-25 2006-10-12 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
NZ513547A (en) * 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
KR101003960B1 (ko) * 2003-08-22 2010-12-30 안티포딘 파마슈티칼스, 인코포레이티드 미토콘드리아 표적화 산화방지제로서 사용되는 미토퀴논 유도체를 포함하는 약제학적 조성물
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
KR20070030815A (ko) * 2004-07-13 2007-03-16 오리디스 비오메드 포르슝스-운트 엔트비크룽스 게엠베하 간질환 및 상피암의 치료에서 미토콘드리아적으로 표적화된산화방지제의 용도
US7750018B2 (en) * 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
WO2010121177A2 (en) 2009-04-17 2010-10-21 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
KR101621418B1 (ko) 2014-03-19 2016-05-23 울산과학기술원 미토콘드리아 표적화된 항-종양 조성물
CA3164800A1 (en) 2019-12-16 2021-06-24 Unist(Ulsan National Institute Of Science And Technology) Compound for inhibiting neovascularization factors and use thereof

Also Published As

Publication number Publication date
KR20210076875A (ko) 2021-06-24
CN114901290B (zh) 2024-09-03
EP4079309A1 (en) 2022-10-26
CN114901290A (zh) 2022-08-12
EP4079309A4 (en) 2024-01-10
CA3164800A1 (en) 2021-06-24
AU2020409912A1 (en) 2022-06-16
US12545695B2 (en) 2026-02-10
JP7831775B2 (ja) 2026-03-17
US20230088747A1 (en) 2023-03-23
JP2023506838A (ja) 2023-02-20
WO2021125800A1 (ko) 2021-06-24

Similar Documents

Publication Publication Date Title
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
BR112021022457A2 (pt) Inibidores de fgfr e métodos de uso dos mesmos
BR112021016620A2 (pt) Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112018008918A8 (pt) compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
CL2018001996A1 (es) Composiciones y métodos para modular la expresión del factor b del complemento (divisional de solicitud 2764-16)
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
BR112015023760A2 (pt) compostos e composições terapêuticas
CL2017001050A1 (es) Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
JOP20210050A1 (ar) معدلات تعبير pnpla3
BR112018070859A2 (pt) degradantes da proteína de bet
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
BR112022000713A2 (pt) Imidazopirimidinas como inibidores de eed e o uso das mesmas
EA201792116A1 (ru) Ингибитор янус-киназы
BR112018008103A2 (pt) análogos de celastrol
EA201591339A1 (ru) Тиазолкарбоксамиды и пиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
EP4364743A3 (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
MX2019012938A (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
CO2022000481A2 (es) Inhibidores de enzimas
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
CL2021000580A1 (es) Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares.
BR112017022958A2 (pt) métodos para tratamento de câncer com inibidor da via da stat3 e inibidor de quinase

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]